{"id":"https://openalex.org/W7108484455","doi":"https://doi.org/10.1182/blood-2025-3428","title":"Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML","display_name":"Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML","publication_year":2025,"publication_date":"2025-11-03","ids":{"openalex":"https://openalex.org/W7108484455","doi":"https://doi.org/10.1182/blood-2025-3428"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2025-3428","doi":"https://doi.org/10.1182/blood-2025-3428","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2025-3428","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Ghayas Issa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ghayas Issa","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hagop Kantarjian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop Kantarjian","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Musa Yilmaz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Musa Yilmaz","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Nicholas Short","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas Short","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tapan Kadia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tapan Kadia","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Georgina El Hajjar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Georgina El Hajjar","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Courtney DiNardo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Courtney DiNardo","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yesid Alvarado","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yesid Alvarado","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Elias Jabbour","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elias Jabbour","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Gautam Borthakur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gautam Borthakur","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Naveen Pemmaraju","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naveen Pemmaraju","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Farhad Ravandi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farhad Ravandi","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Andreeff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Andreeff","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Guillermo Garcia-Manero","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guillermo Garcia-Manero","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":null,"display_name":"Naval Daver","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naval Daver","raw_affiliation_strings":["1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"146","issue":"Supplement 1","first_page":"3428","last_page":"3428"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ziftomenib","display_name":"ziftomenib","score":0.996999979019165},{"id":"https://openalex.org/keywords/quizartinib","display_name":"quizartinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.8989999890327454},{"id":"https://openalex.org/keywords/relapsed-refractory-aml","display_name":"relapsed/refractory AML","score":0.9649999737739563},{"id":"https://openalex.org/keywords/flt3-inhibition","display_name":"FLT3 inhibition","score":0.9340000152587891},{"id":"https://openalex.org/keywords/mll-rearrangement","display_name":"MLL rearrangement","score":0.8339999914169312},{"id":"https://openalex.org/keywords/npm1-mutation","display_name":"NPM1 mutation","score":0.8870000243186951},{"id":"https://openalex.org/keywords/nup98-rearrangement","display_name":"NUP98 rearrangement","score":0.9089999794960022},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6830000281333923},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.9240000247955322},{"id":"https://openalex.org/keywords/meis1","display_name":"MEIS1","score":0.5979999899864197},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.6209999918937683}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6373000144958496},{"id":"https://openalex.org/C2483381","wikidata":"https://www.wikidata.org/wiki/Q18030194","display_name":"NPM1","level":5,"score":0.5982999801635742},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.492900013923645},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.44429999589920044},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43709999322891235},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.43070000410079956},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.39649999141693115},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35659998655319214},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3343000113964081},{"id":"https://openalex.org/C2910954276","wikidata":"https://www.wikidata.org/wiki/Q14912399","display_name":"Fms-Like Tyrosine Kinase 3","level":4,"score":0.3328999876976013},{"id":"https://openalex.org/C194409129","wikidata":"https://www.wikidata.org/wiki/Q103824","display_name":"Hematology","level":2,"score":0.32019999623298645},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31529998779296875},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2953000068664551},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.2847999930381775},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.2797999978065491},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.2782999873161316},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.2700999975204468},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2648000121116638},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.263700008392334},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.26109999418258667},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.25780001282691956},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.2574999928474426}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2025-3428","doi":"https://doi.org/10.1182/blood-2025-3428","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2025-3428","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.4027293622493744}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"and":[2,59,79,97,132,159,181,189,222,254,373,400,422,452,472,488,491,498,516,520],"Significance":[3],"The":[4,389],"menin-KMT2A":[5,68],"interaction":[6],"is":[7,45,64,107,133,151,192,260,308,345,358,396],"a":[8,46,74,102,108,171,193,434,539],"dependency":[9],"in":[10,33,82,114,137,146,161,183,208,245,251,262,296,304,333,366,414],"acute":[11],"leukemia":[12,87,264],"caused":[13],"by":[14,27,291,449,524],"either":[15],"rearrangement":[16],"of":[17,29,50,56,62,77,94,176,206,233,242,249,258,266,282,294,302,363,370,386,392,419,478,485,493,506,518,526,549],"the":[18,52,60,67,138,174,177,238,247,292,317,328,346,393,401,415,420,427,443,479,546],"KMT2A":[19],"(KMT2Ar)":[20],"or":[21,26,85,224,226],"Nucleoporin":[22],"98":[23],"(NUP98r)":[24],"genes,":[25,58],"mutation":[28],"NPM1":[30],"(NPM1mt).":[31],"Mutations":[32],"FLT3":[34,44,90,98,110,234,243,259,267,273,283,450],"commonly":[35],"co-occur":[36],"with":[37,89,116,156,210,228,306,320,330,433,455,470,508,551],"these":[38,279],"genotypes":[39,248],"susceptible":[40],"to":[41,73,101,310,315,341,368,383,397,408,457,538],"menin":[42,96,154,178],"inhibition.":[43],"putative":[47],"transcriptional":[48,75],"target":[49,277,435],"MEIS1,":[51],"DNA":[53],"binding":[54],"co-factor":[55],"HOX":[57],"expression":[61,257],"MEIS1":[63],"dependent":[65],"on":[66,360,512],"interaction.":[69],"Menin":[70],"inhibition":[71,274],"leads":[72],"suppression":[76],"FLT3,":[78],"preclinical":[80],"data":[81],"KMT2Ar,":[83,225],"NPM1mt":[84],"NUP98r":[86,227],"models":[88],"co-mutation":[91],"show":[92],"synergy":[93],"combined":[95],"inhibition,":[99],"leading":[100],"profound":[103],"antileukemic":[104],"effect.":[105],"Quizartinib":[106],"potent":[109],"inhibitor,":[111],"currently":[112,134,530],"approved":[113],"combination":[115,175,209,305,318,454,544],"high-intensity":[117],"chemotherapy,":[118],"then":[119],"as":[120,327,351],"maintenance":[121],"monotherapy":[122],"for":[123,467,545],"newly":[124],"diagnosed":[125],"FLT3-ITD":[126,147],"positive":[127],"AML":[128,164,185],"(Erba,":[129],"Lancet":[130,166],"2023),":[131],"being":[135],"evaluated":[136],"global":[139],"phase":[140,200,348,394,403],"3":[141],"randomized,":[142],"placebo-controlled":[143],"trial":[144,502],"QuANTUM-Wild":[145],"negative":[148],"AML.":[149,298,335,552],"Ziftomenib":[150,336],"an":[152],"investigational":[153],"inhibitor":[155,179],"demonstrated":[157],"efficacy":[158],"safety":[160,399,471],"relapsed/refractory":[162,184],"(R/R)":[163],"(Wang,":[165],"Oncology":[167],"2024).":[168],"We":[169],"designed":[170],"study":[172,202,253],"investigating":[173],"ziftomenib":[180,207,303,319],"quizartinib":[182,211,295,307,321],"(NCT06769490).":[186],"Study":[187],"Design":[188],"Methods":[190],"This":[191,286,501,528],"single":[194,198],"arm,":[195],"open":[196],"label,":[197],"center":[199],"1":[201,365],"evaluating":[203],"escalating":[204],"doses":[205],"at":[212,322,533],"40":[213],"mg":[214,324],"PO":[215,325],"daily.":[216],"Patients":[217],"age":[218],"\u2265":[219],"18":[220],"years,":[221],"NPM1mt,":[223],"R/RAML":[229],"are":[230,381],"eligible":[231],"regardless":[232,265,281],"mutational":[235,268,284],"status.":[236,285],"Given":[237],"relatively":[239],"higher":[240,261],"occurrence":[241],"mutations":[244],"all":[246,278],"interest":[250],"this":[252],"given":[255],"that":[256,272],"KMT2Ar":[263],"status,":[269],"we":[270,313,441],"hypothesize":[271],"could":[275,536],"therapeutically":[276],"leukemias":[280],"observation":[287],"has":[288],"been":[289],"bolstered":[290],"activity":[293,332],"FLT3-wildtype":[297,334],"Therefore,":[299],"if":[300,378],"escalation":[301,417,423],"found":[309],"be":[311,338,376,412,465],"safe,":[312],"plan":[314],"explore":[316],"60":[323],"daily":[326],"dose":[329,350,405,416],"single-agent":[331],"will":[337,375,411,424,464],"escalated":[339],"up":[340,456],"600":[342],"mg,":[343],"which":[344],"recommended":[347,402],"2":[349],"monotherapy.":[352],"A":[353],"bone":[354],"marrow":[355],"(BM)":[356],"biopsy":[357],"planned":[359],"day":[361],"14":[362],"cycle":[364,371],"addition":[367],"end":[369],"assessment":[372,477],"treatment":[374,453],"held":[377],"BM":[379],"blasts":[380],"<5%":[382],"improve":[384],"chances":[385],"count":[387],"recovery.":[388],"primary":[390],"objective":[391],"I":[395],"determine":[398,442],"II":[404],"(RP2D).":[406],"Up":[407],"24":[409],"pts":[410],"included":[413],"portion":[418],"study,":[421,529],"proceed":[425],"using":[426,522],"Bayesian":[428],"optimal":[429],"interval":[430],"(BOIN)":[431],"design":[432],"dose-limiting":[436],"toxicity":[437],"rate":[438],"<20%.":[439],"Once":[440],"RP2D,":[444],"two":[445],"expansion":[446,462],"cohorts":[447],"stratified":[448],"status":[451],"10":[458],"patients":[459,532,550],"per":[460],"separate":[461],"cohort":[463],"enrolled":[466],"additional":[468],"experience":[469],"efficacy.":[473],"Secondary":[474],"objectives":[475,510],"include":[476],"composite":[480],"complete":[481],"remission":[482],"rate,":[483],"duration":[484],"response,":[486],"event-free":[487],"overall":[489],"survival":[490],"concordance":[492],"genetic":[494],"(NGS,":[495],"Invivoscribe,":[496],"USA)":[497],"flow":[499],"MRD.":[500],"includes":[503],"longitudinal":[504],"collection":[505],"samples,":[507],"exploratory":[509],"focused":[511],"improving":[513],"MRD":[514],"detection,":[515],"understand":[517],"response":[519],"resistance":[521],"cytometry":[523],"time":[525],"flight.":[527],"enrolling":[531],"MD":[534],"Anderson,":[535],"lead":[537],"novel":[540],"all-oral":[541],"targeted":[542],"therapy":[543],"largest":[547],"subset":[548]},"counts_by_year":[{"year":2026,"cited_by_count":3}],"updated_date":"2026-09-30T09:27:27.532063","created_date":"2025-12-04T00:00:00"}